Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 127 entries
Sorted by: Best Match Show Resources per page
Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study.

Current therapeutic research, clinical and experimental

Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S.
PMID: 24672118
Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002.

BACKGROUND: The Recover Study is an ongoing, prospective study designed 10 to assess toxicity associated with the use of nucleoside analogue reverse transcriptase inhibitors (NRTIs) (stavudine, zidovudine, lamivudine, didanosine, abacavir) in HIV-1-infected patients receiving highly active antiretroviral therapy (HAART)...

Cite
Palacios R, Santos J, Camino X, et al. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005;66(2):117-29doi: 10.1016/j.curtheres.2005.04.002.
Palacios, R., Santos, J., Camino, X., Arazo, P., Torres Perea, R., Echevarrfa, S., Ribera, E., Sánchez de la Rosa, R., Moreno Guillen, S. (2005). Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Current therapeutic research, clinical and experimental, 66(2), 117-29. https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios, Rosario, et al. "Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study." Current therapeutic research, clinical and experimental vol. 66,2 (2005): 117-29. doi: https://doi.org/10.1016/j.curtheres.2005.04.002
Palacios R, Santos J, Camino X, Arazo P, Torres Perea R, Echevarrfa S, Ribera E, Sánchez de la Rosa R, Moreno Guillen S. Treatment-limiting toxicities associated withnucleoside analogue reverse transcriptase inhibitor therapy: A prospective, observational study. Curr Ther Res Clin Exp. 2005 Mar;66(2):117-29. doi: 10.1016/j.curtheres.2005.04.002. PMID: 24672118; PMCID: PMC3964549.
Copy Download .nbib Format: NLM
Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.

AIDS research and therapy

Sanders-Beer BE, Spano YY, Golighty D, Lara A, Hebblewaite D, Nieves-Duran L, Rhodes L, Mansfield KG.
PMID: 21255437
AIDS Res Ther. 2011 Jan 21;8(1):3. doi: 10.1186/1742-6405-8-3.

BACKGROUND: In many preclinical AIDS research studies, antiretroviral therapy (ART) is administered to experimentally simian immunodeficiency (SIV)-infected rhesus macaques for reduction of viral load to undetectable levels. Prolonged treatment of macaques with a high dose of PMPA (9-[2-(r)-(phosphonomethoxy) propyl]...

Cite
Sanders-Beer BE, Spano YY, Golighty D, et al. Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy. AIDS Res Ther. 2011;8(1):3doi: 10.1186/1742-6405-8-3.
Sanders-Beer, B. E., Spano, Y. Y., Golighty, D., Lara, A., Hebblewaite, D., Nieves-Duran, L., Rhodes, L., & Mansfield, K. G. (2011). Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy. AIDS research and therapy, 8(1), 3. https://doi.org/10.1186/1742-6405-8-3
Sanders-Beer, Brigitte E, et al. "Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy." AIDS research and therapy vol. 8,1 (2011): 3. doi: https://doi.org/10.1186/1742-6405-8-3
Sanders-Beer BE, Spano YY, Golighty D, Lara A, Hebblewaite D, Nieves-Duran L, Rhodes L, Mansfield KG. Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy. AIDS Res Ther. 2011 Jan 21;8(1):3. doi: 10.1186/1742-6405-8-3. PMID: 21255437; PMCID: PMC3038877.
Copy Download .nbib Format: NLM
An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014.

Acta pharmaceutica Sinica. B

De Clercq E.
PMID: 26713268
Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 02.

No abstract available.

Cite
De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015;5(6):520-43doi: 10.1016/j.apsb.2015.09.001.
De Clercq, E. (2015). An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta pharmaceutica Sinica. B, 5(6), 520-43. https://doi.org/10.1016/j.apsb.2015.09.001
De Clercq, Erik. "An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014." Acta pharmaceutica Sinica. B vol. 5,6 (2015): 520-43. doi: https://doi.org/10.1016/j.apsb.2015.09.001
De Clercq E. An Odyssey in antiviral drug development-50 years at the Rega Institute: 1964-2014. Acta Pharm Sin B. 2015 Nov;5(6):520-43. doi: 10.1016/j.apsb.2015.09.001. Epub 2015 Nov 02. PMID: 26713268; PMCID: PMC4675811.
Copy Download .nbib Format: NLM
The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs.

Frontiers in immunology

Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR.
PMID: 27242802
Front Immunol. 2016 May 23;7:199. doi: 10.3389/fimmu.2016.00199. eCollection 2016.

The Surveillance Monitoring for ART Toxicities (SMARTT) cohort of the Pediatric HIV/AIDS Cohort Study includes over 3,500 HIV-exposed but uninfected infants and children at 22 sites in the US, including Puerto Rico. The goal of the study is to...

Cite
Van Dyke RB, Chadwick EG, Hazra R, et al. The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Front Immunol. 2016;7:199doi: 10.3389/fimmu.2016.00199.
Van Dyke, R. B., Chadwick, E. G., Hazra, R., Williams, P. L., & Seage, G. R. (2016). The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Frontiers in immunology, 7199. https://doi.org/10.3389/fimmu.2016.00199
Van Dyke, Russell B, et al. "The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs." Frontiers in immunology vol. 7 (2016): 199. doi: https://doi.org/10.3389/fimmu.2016.00199
Van Dyke RB, Chadwick EG, Hazra R, Williams PL, Seage GR. The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral Drugs. Front Immunol. 2016 May 23;7:199. doi: 10.3389/fimmu.2016.00199. eCollection 2016. PMID: 27242802; PMCID: PMC4876360.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 12616965
Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002;24(10):703-29
Bayés, M., Rabasseda, X., & Prous, J. R. (2002). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 24(10), 703-29.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 24,10 (2002): 703-29.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Dec;24(10):703-29. PMID: 12616965.
Copy Download .nbib Format: NLM
Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study.

International journal of immunopathology and pharmacology

Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A.
PMID: 12590875
Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208.

Resistance to nucleoside reverse transcriptase inhibitors (NRTIs) was studied in 527 HIV-1-infected patients, 342 responder and 185 non-responder to two NRTIs. Responders were followed for one year to assess the incidence of clinical failure. The prevalence of the 215Y/F...

Cite
Gianotti N, Setti M, Manconi PE, et al. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002;15(2):129-139doi: 10.1177/039463200201500208.
Gianotti, N., Setti, M., Manconi, P. E., Leoncini, F., Chiodo, F., Minoli, L., Moroni, M., Angarano, G., Mazzotta, F., Carosi, G., Antonelli, G., & Lazzarin, A. (2002). Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. International journal of immunopathology and pharmacology, 15(2), 129-139. https://doi.org/10.1177/039463200201500208
Gianotti, N., et al. "Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study." International journal of immunopathology and pharmacology vol. 15,2 (2002): 129-139. doi: https://doi.org/10.1177/039463200201500208
Gianotti N, Setti M, Manconi PE, Leoncini F, Chiodo F, Minoli L, Moroni M, Angarano G, Mazzotta F, Carosi G, Antonelli G, Lazzarin A. Reverse transcriptase mutations in HIV-1 infected patients treated with two nucleoside analogues: the SMART study. Int J Immunopathol Pharmacol. 2002 May-Aug;15(2):129-139. doi: 10.1177/039463200201500208. PMID: 12590875.
Copy Download .nbib Format: NLM
Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting.

Journal of translational medicine

Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O, Mucheche M, Rusakaniko S, Katzenstein DA.
PMID: 16907973
J Transl Med. 2006 Aug 14;4:33. doi: 10.1186/1479-5876-4-33.

BACKGROUND: The World Health Organization (WHO)'s "3 x 5 program" has spurred efforts to place 3 million people on combination antiretroviral therapy (ART) for treatment of AIDS in resource-limited countries. Paradoxically, the cost of CD4+ T-lymphocyte count essential for...

Cite
Zijenah LS, Kadzirange G, Madzime S, et al. Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med. 2006;4:33doi: 10.1186/1479-5876-4-33.
Zijenah, L. S., Kadzirange, G., Madzime, S., Borok, M., Mudiwa, C., Tobaiwa, O., Mucheche, M., Rusakaniko, S., & Katzenstein, D. A. (2006). Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. Journal of translational medicine, 433. https://doi.org/10.1186/1479-5876-4-33
Zijenah, Lynn S, et al. "Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting." Journal of translational medicine vol. 4 (2006): 33. doi: https://doi.org/10.1186/1479-5876-4-33
Zijenah LS, Kadzirange G, Madzime S, Borok M, Mudiwa C, Tobaiwa O, Mucheche M, Rusakaniko S, Katzenstein DA. Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting. J Transl Med. 2006 Aug 14;4:33. doi: 10.1186/1479-5876-4-33. PMID: 16907973; PMCID: PMC1586214.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Bayés M, Rabasseda X, Prous JR.
PMID: 16082422
Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72.

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug...

Cite
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27(5):331-72
Bayés, M., Rabasseda, X., & Prous, J. R. (2005). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 27(5), 331-72.
Bayés, M, et al. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 27,5 (2005): 331-72.
Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jun;27(5):331-72. PMID: 16082422.
Copy Download .nbib Format: NLM
Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Torres RA, Cadman JA.
PMID: 18034560
BioDrugs. 2000 Aug;14(2):83-91. doi: 10.2165/00063030-200014020-00002.

HIV infection recently has been complicated by the emergence of a rare metabolic dysmorphic disorder characterised by fat atrophy, redistribution and accumulation in the setting of hyperlipidaemia and, on occasion, hyperglycaemia. The disorder, sometimes referred to as HIV-associated Adipose...

Cite
Torres RA, Cadman JA. Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome. BioDrugs. 2000;14(2):83-91doi: 10.2165/00063030-200014020-00002.
Torres, R. A., & Cadman, J. A. (2000). Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 14(2), 83-91. https://doi.org/10.2165/00063030-200014020-00002
Torres, R A, and Cadman, J A. "Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 14,2 (2000): 83-91. doi: https://doi.org/10.2165/00063030-200014020-00002
Torres RA, Cadman JA. Potential of recombinant human growth hormone in HIV-associated adipose redistribution syndrome. BioDrugs. 2000 Aug;14(2):83-91. doi: 10.2165/00063030-200014020-00002. PMID: 18034560.
Copy Download .nbib Format: NLM
Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies.

Mitochondrion

McComsey GA, Walker UA.
PMID: 16120376
Mitochondrion. 2004 Jul;4(2):111-8. doi: 10.1016/j.mito.2004.05.008.

Lipoatrophy is a selective loss of subcutaneous adipose tissue and a highly prevalent complication of antiretroviral therapy (ART). This form of fat wasting is associated with decreased quality of life, disincentive for adherence to antiretroviral therapy, as well as...

Cite
McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion. 2004;4(2):111-8doi: 10.1016/j.mito.2004.05.008.
McComsey, G. A., & Walker, U. A. (2004). Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion, 4(2), 111-8. https://doi.org/10.1016/j.mito.2004.05.008
McComsey, Grace A, and Walker, Ulrich A. "Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies." Mitochondrion vol. 4,2 (2004): 111-8. doi: https://doi.org/10.1016/j.mito.2004.05.008
McComsey GA, Walker UA. Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion. 2004 Jul;4(2):111-8. doi: 10.1016/j.mito.2004.05.008. PMID: 16120376.
Copy Download .nbib Format: NLM
LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.

Southern African journal of HIV medicine

Innes S, Levin L, Cotton M.
PMID: 20706598
South Afr J HIV Med. 2009 Dec;10(4):76-80. doi: 10.4102/sajhivmed.v10i4.264.

Lipodystrophy syndrome (LD) is common in HIV-infected children, particularly those taking didanosine, stavudine or zidovudine. Lipo-atrophy in particular causes major stigmatisation and interferes with adherence. In addition, LD may have significant long-term health consequences, particularly cardiovascular. Since the stigmatising...

Cite
Innes S, Levin L, Cotton M. LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. South Afr J HIV Med. 2009;10(4):76-80doi: 10.4102/sajhivmed.v10i4.264.
Innes, S., Levin, L., & Cotton, M. (2009). LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. Southern African journal of HIV medicine, 10(4), 76-80. https://doi.org/10.4102/sajhivmed.v10i4.264
Innes, Steve, et al. "LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART." Southern African journal of HIV medicine vol. 10,4 (2009): 76-80. doi: https://doi.org/10.4102/sajhivmed.v10i4.264
Innes S, Levin L, Cotton M. LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART. South Afr J HIV Med. 2009 Dec;10(4):76-80. doi: 10.4102/sajhivmed.v10i4.264. PMID: 20706598; PMCID: PMC2919754.
Copy Download .nbib Format: NLM
Efavirenz DuPont Pharmaceuticals Co.

IDrugs : the investigational drugs journal

Dong BJ.
PMID: 18465625
IDrugs. 1998 Oct;1(6):700-11.

Efavirenz is the lead compound of a series of benzoxazinones originally developed by DuPont Merck. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for the potential treatment of viral infections, including HIV. In June 1998, the company...

Cite
Dong BJ. Efavirenz DuPont Pharmaceuticals Co. IDrugs. 1998;1(6):700-11
Dong, B. J. (1998). Efavirenz DuPont Pharmaceuticals Co. IDrugs : the investigational drugs journal, 1(6), 700-11.
Dong, B J. "Efavirenz DuPont Pharmaceuticals Co." IDrugs : the investigational drugs journal vol. 1,6 (1998): 700-11.
Dong BJ. Efavirenz DuPont Pharmaceuticals Co. IDrugs. 1998 Oct;1(6):700-11. PMID: 18465625.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 127 entries